Byington RP - Search Results

1

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Byington RP, et al. Circulation. 1995 Nov 1;92(9):2419-25. doi: 10.1161/01.cir.92.9.2419. Circulation. 1995. PMID: 7586340

2

Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD. Crouse JR, et al. Among authors: byington rp. Control Clin Trials. 1992 Dec;13(6):495-506. doi: 10.1016/0197-2456(92)90206-f. Control Clin Trials. 1992. PMID: 1334821 Clinical Trial.

3

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).

Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG. Byington RP, et al. Am J Cardiol. 1995 Sep 28;76(9):54C-59C. doi: 10.1016/s0002-9149(99)80471-8. Am J Cardiol. 1995. PMID: 7572688 Clinical Trial.

4

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.

Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME. Furberg CD, et al. Among authors: byington rp. Am J Cardiol. 1995 Sep 28;76(9):60C-63C. doi: 10.1016/s0002-9149(99)80472-x. Am J Cardiol. 1995. PMID: 7572689 Clinical Trial.

5

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, et al. Furberg CD, et al. Among authors: byington rp. Circulation. 1994 Oct;90(4):1679-87. doi: 10.1161/01.cir.90.4.1679. Circulation. 1994. PMID: 7734010 Clinical Trial.

6

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).

Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Crouse JR 3rd, et al. Among authors: byington rp. Am J Cardiol. 1995 Mar 1;75(7):455-9. doi: 10.1016/s0002-9149(99)80580-3. Am J Cardiol. 1995. PMID: 7863988 Clinical Trial.

7

Pravastatin, lipids, and major coronary events.

Furberg CD, Byington RP, Crouse JR, Espeland MA. Furberg CD, et al. Among authors: byington rp. Am J Cardiol. 1994 Jun 1;73(15):1133-4. doi: 10.1016/0002-9149(94)90297-6. Am J Cardiol. 1994. PMID: 8198043 Clinical Trial. No abstract available.

8

[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Byington RP, et al. Fortschr Med. 1996 Mar 20;114(8):91-8. Fortschr Med. 1996. PMID: 8647574 German.

9

Reductase inhibitor monotherapy and stroke prevention.

Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD. Crouse JR 3rd, et al. Among authors: byington rp. Arch Intern Med. 1997 Jun 23;157(12):1305-10. Arch Intern Med. 1997. PMID: 9201004

10

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB. Byington RP, et al. Am J Cardiol. 1997 Oct 15;80(8):1087-90. doi: 10.1016/s0002-9149(97)00611-5. Am J Cardiol. 1997. PMID: 9352986

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page